Shire plc, of Dublin, disclosed top-line phase III data with Vyvanse (lisdexamfetamine dimesylate) capsules as an adjunctive treatment for major depressive disorder in adults who inadequately responded to antidepressant monotherapy with a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor.